Minimally Invasive Treatment Options for BPH Remain Critical Due to Shortcomings of Surgery and Medication
Read MoreResults from Multi-Center Study Support the Application of Minimally Invasive Treatment for Broader BPH Population
Read MoreTeleflex Announces Expanded Nationwide Coverage for the UroLift System for Patients with Enlarged Prostate
June 26, 2019
Coverage Decision by Anthem Increases Access to Minimally Invasive Treatment, Offering Patients Rapid, Durable Symptom Relief
Read More
Real-World Data Presented at American Urological Association Meeting Highlight Consistency with Controlled Studies and Effectiveness in Diverse Patient Populations
Data featuring real-world findings in a large, multi-center study, and effectiveness and sexual function preservation in diverse patient populations to be presented at the Annual Meeting of the American Urological Association
Read More
Read More
Teleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift® System to Treat Patients with Enlarged Prostate
March 20, 2019
Findings Presented at European Association of Urology Show Consistent Positive Results for Minimally Invasive UroLift System Treatment
Read MoreNeoTract Announces 100,000 Patients Treated for Enlarged Prostate with UroLift® System
February 21, 2019
Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life, While Preserving Sexual Function*1,2
Read MoreNeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate
February 14, 2019
Favorable Coverage Decisions Broaden Access to This Minimally Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms
Read MoreNeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage or of Treatment Options
Read More12-Month Results from Study of NeoTract’s UroLift® System for BPH in Men with an Obstructive Median Lobe Published in Prostate Cancer and Prostatic Diseases
December 14, 2018
PLEASANTON, Calif. – December 14, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the publication of 12-month data from the multi-center prospective MedLift™ Study of the UroLift® System treatment for Benign Prostatic Hyperplasia (BPH) in patients with an obstructive median lobe. Results were published in Prostate Cancer and Prostatic Diseases, a Nature Publishing Group journal.
Read More